Vedant Fashions board approves executive redesignation and stock options

Vedant Fashions Limited announced that its Board of Directors, in a meeting held on November 05, 2026, approved the re-designation of Mr. Aman Kumar Gupta from Chief Retail Officer to Chief Business Officer, effective November 06, 2026. Additionally, the board sanctioned the grant of 9,887 stock options under the VFL Employee Stock Option Scheme 2018 to eligible employees. The meeting concluded at 04:10 p.m.

Vedant Fashions Board Meeting Highlights

In a significant development, the Board of Directors of Vedant Fashions Limited convened on Thursday, November 05, 2026, to discuss and approve key corporate actions. The meeting, which commenced at 02:50 p.m. and concluded at 04:10 p.m., resulted in two primary approvals concerning senior management and employee incentives.

Executive Re-designation

Following a recommendation from the Nomination and Remuneration Committee, the Board approved the re-designation of Mr. Aman Kumar Gupta, who previously held the position of Chief Retail Officer. Effective November 06, 2026, Mr. Gupta will assume the role of Chief Business Officer of the Company. He will continue to be recognized as Senior Management, in accordance with Regulation 16(1)(d) of the Listing Regulations. Further details pertaining to this redesignation are provided in Annexure A.

Grant of Stock Options

The Board also sanctioned the grant of 9,887 stock options to eligible employees. These options are to be issued under the VFL Employee Stock Option Scheme 2018 – Scheme Pratham, as amended, and read in conjunction with the VFL Employee Stock Option Plan 2018, as amended. The grant was made based on the recommendation of the Nomination and Remuneration Committee. Details regarding the stock options grant are enclosed as Annexure -B.

Information Dissemination

The Company has made this information available on its website at www.vedantfashions.com, ensuring transparency and accessibility for all stakeholders.

Source: BSE

Previous Article

CORONA Remedies reports 22% revenue growth in Q2 FY27